Adamas Pharmaceuticals to Present at Two Upcoming Healthcare Conferences

Monday, February 22, 2016 9:05 PM UTC

EMERYVILLE, Calif., Feb. 22, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at two upcoming healthcare conferences--

The 36^th Annual Cowen and Company Healthcare Conference
Tuesday, March 8, 2016 at 10:40 a.m. ET
Boston, MA

The 15^th Annual Needham Healthcare Conference
Tuesday, April 12, 2016 at 12:10 p.m. ET
New York, NY

The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for replay for approximately two weeks after the presentation dates.

About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company is also evaluating ADS-4101, an extended-release version of an FDA-approved single-agent compound for the treatment of epilepsy. The company's portfolio also includes Namzaric™ and Namenda XR^®, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.

Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR^® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

For questions, please contact:

Susan Lehner
Investor Relations & Corporate Communications
Adamas Pharmaceuticals, Inc.
Phone: 510-450-3567

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Adamas Pharmaceuticals to Present at Two Upcoming Healthcare Conferences

Editor's Picks

Welcome to EconoTimes